Galecto Announces First Patient Dosed In Investigator-Initiated Phase 2 Trial Of GB1211 In Combination With Pembrolizumab
Galecto Announces First Patient Dosed In Investigator-Initiated Phase 2 Trial Of GB1211 In Combination With Pembrolizumab
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.